Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
The conference highlighted research suggesting that deuterium levels may influence key biological processes
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
Subscribe To Our Newsletter & Stay Updated
